Clinicopathological Implications of IDH1 Mutation and Ki-67 Expression Across WHO Grades of Gliomas: Insights from a Prospective Observational Study.

Authors

Khushboo Sinha, Sudha Iyengar, Reema Bhushan, Avinash Sharma

Published in

Iranian journal of pathology. Volume 21. Issue 4. Pages 595-607. Sep 01, 2026. Epub Aug 01, 2026.

Abstract

Gliomas are heterogeneous central nervous system tumors with variable outcomes. Accurate classification using histopathological and molecular markers, such as IDH1 R132H mutation and Ki-67 index, is essential. This study evaluated their distribution across glioma grades and correlation with clinicopathological parameters.
This prospective observational study included 90 histologically confirmed glioma cases. Hematoxylin and eosin (H&E)-stained sections were graded according to WHO 2021 criteria. Immunohistochemistry was used to assess IDH1 R132H mutation status and Ki-67 labeling index. Associations between variables were analyzed using chi-square and logistic regression.
Astrocytomas (55/90, 61.1%) and glioblastomas (24/90, 26.7%) were the most common tumor types. IDH1 R132H mutation was detected in 65/90 cases (72.2%). Grade-wise, mutation positivity was highest in grade II (28/28, 100%), followed by grade I (8/9, 88.9%) and grade III (20/26, 76.9%), whereas grade IV glioblastomas showed significantly lower positivity (9/27, 33.3%). Ki-67 expression increased with tumor grade, with >20% expression in 26/27 grade IV tumors (96.3%). A significant inverse correlation was observed between IDH1 mutation status and Ki-67 level (P < 0.0001). Logistic regression showed that younger age was significantly associated with IDH1 mutation (P = 0.001), while IDH1 wild-type status correlated with older age (P = 0.024).
IDH1 R132H mutation and Ki-67 index correlate with glioma grade and age, supporting their routine use in classification. In the absence of survival data, the present results reflect clinicopathological associations rather than validated prognostic predictions; prospective studies incorporating survival outcomes are needed to confirm the prognostic utility of these markers.

PMID:
42605490
Bibliographic data and abstract were imported from PubMed on 17 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.